Clinical TrialID 7970
A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
NCT06039826
Overweight
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 7970
- Evidence Id
- 7970
- Core Evidence Id
- 7970
- Source Clinical Trial Id
- 7966
- Herb2 Clinical Trial Id
- HBCT007966
- Nct Id
- NCT06039826
- Title
- A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
- Status
- Completed
- Phase
- Phase 1
- Study Result
- No
- Study Condition
- Overweight
- Study Type
- Interventional
- Study Design
- Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: BASIC_SCIENCE
- Intervention
- DRUG: LY3437943|DRUG: Ethinyl Estradiol|DRUG: Drospirenone
- Intervention Allocation
- Non_Randomized
- Intervention Model
- Sequential
- Intervention Mask
- Intervention Purpose
- Basic_Science
- Gender
- Female
- Age
- Adult
- Enrollment
- 46
- Outcome Measure
- Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time zero to 24 Hours Postdose (AUC0-24) of Ethinyl Estradiol, PK: AUC0-24 of Ethinyl Estradiol, Predose on Day 1 up to 144 days postdose|PK: Maximum Observed Concentration (Cmax) of Ethinyl Estradiol, PK: Cmax of Ethinyl Estradiol, Predose on Day 1 up to 144 days postdose|PK: Time of Maximum Observed Concentration (Tmax) of Ethinyl Estradiol, PK: Tmax of Ethinyl Estradiol, Predose on Day 1 up to 144 days postdose|PK: Area Under the Concentration Versus Time Curve from Time zero to 24 Hours Postdose (AUC0-24) of Drospirenone, PK: AUC0-24 of Drospirenone, Predose on Day 1 up to 144 days postdose|PK: Maximum Observed Concentration (Cmax) of Drospirenone, PK: Cmax of Drospirenone, Predose on Day 1 up to 144 days postdose|PK: Time of Maximum Observed Concentration (Tmax) of Drospirenone, PK: Tmax of Drospirenone, Predose on Day 1 up to 144 days postdose
- Sponsor Collaborator
- Eli Lilly and Company
- Funded By
- INDUSTRY
- Location
- Qps-Mra, Llc, South Miami, Florida, 33143, United States|ICON Early Phase Services, San Antonio, Texas, 78209, United States
- Other Id
- 18533|J1I-MC-GZBV
- Start Date
- 2023-09-12
- Primary Completion Date
- 2024-07-11
- Completion Date
- 2024-07-11
- First Posted
- 2023-09-15
- Results First Posted
- Last Update Posted
- 2024-07-26
- Study Document
- Study Url
- https://clinicaltrials.gov/study/NCT06039826
- Title Cn
- Title En
- A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
- Bilingual Status
- semi_complete